Skip to main content

Outlook Therapeutics, Inc. (OTLK) Stock Forecast

Data as of May 3, 2026

Healthcare · Current price $0.27 (+6.40%)

Consensus Target
$1.00
Upside
+275.9%
Analysts
6
Rating
Hold(2.67)

Price Target Range

Low $1.00High $1.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Hold
Strong Buy0
Buy1
Hold2
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Jan 2, 2026Daniil GataulinChardan Capital$1.00+275.9%
Aug 29, 2025Douglas TsaoH.C. Wainwright$1.00+275.9%

OTLK vs Sector & Market

MetricOTLKHealthcare AvgLarge Cap Avg
Analyst Rating2.672.242.41
Analyst Count6818
Target Upside+275.9%+1149.9%+14.9%
P/E Ratio-0.156.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$4M$21M$58M3
2027-09-30$11M$58M$168M3
2028-09-30$6M$23M$58M1
2029-09-30$8M$30M$75M1
2030-09-30$8M$30M$77M1

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$-0.68$-0.52$-0.372
2027-09-30$-0.43$-0.27$-0.133
2028-09-30$-0.45$-0.15$-0.011
2029-09-30$-0.36$-0.12$-0.001
2030-09-30$-0.39$-0.13$-0.011

Frequently Asked Questions

What is the analyst consensus for OTLK?

The consensus among 6 analysts covering Outlook Therapeutics, Inc. (OTLK) is Hold with an average price target of $1.00.

What is the highest price target for OTLK?

The highest price target for OTLK is $1.00, set by Daniil Gataulin at Chardan Capital on 2026-01-02.

What is the lowest price target for OTLK?

The lowest price target for OTLK is $1.00, set by Douglas Tsao at H.C. Wainwright on 2025-08-29.

How many analysts cover OTLK?

6 analysts have issued ratings for Outlook Therapeutics, Inc. in the past 12 months.

Is OTLK a buy or sell right now?

Based on 6 analyst ratings, OTLK has a consensus rating of Hold (2.67/5) with a +275.9% upside to the consensus target of $1.00.

What are the earnings estimates for OTLK?

Analysts estimate OTLK will report EPS of $-0.52 for the period ending 2026-09-30, with revenue estimated at $21M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.